← Amgen

What podcasts say about Amgen

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about Amgen

22 statements · 16 positive · 4 negative · 1 mixed · 1 neutral

  1. Yaron WerberPositiveNov 6, 2026· Biotech Hangout

    Amgen’s phase three Sjögren’s trial produced very strong results.

    “Amgen sort of hit it out of the ballpark in the phase three”

    Listen at 55:00

    Open the episode · Episode 202 - November 6, 2026
  2. Yaron WerberPositiveNov 6, 2026· Biotech Hangout

    Amgen will probably file its obesity pen application in the second half of next year if successful.

    “they're probably going to be filing assuming success in the second half of next year with the pen.”

    Listen at 55:58

    Open the episode · Episode 202 - November 6, 2026
  3. Karen FinermanPositiveNov 4, 2026· CNBC's "Fast Money"

    Amgen is a value investment yielding approximately 6%.

    “this is a value play that pays you 6%”

    Listen at 20:12

    Open the episode · Cracks In The AI Trade… And AMD Reports Results 11/3/26
  4. Tim SeymourPositiveNov 4, 2026· CNBC's "Fast Money"

    Amgen’s replacement drugs are already offsetting patent-expiration revenue losses.

    “Amgen is over the patent cliff already. It's replacement drugs. are already replacing that revenue.”

    Listen at 21:28

    Open the episode · Cracks In The AI Trade… And AMD Reports Results 11/3/26
  5. Amgen could become an attractive pullback buy depending on tomorrow’s action.

    “it could end up being a great pullback buy here depending on what the pullback looks like tomorrow.”

    Listen at 27:03

    Open the episode · AI, Chip Stocks Lead Nasdaq Rebound: AMD, Methanex, Hilton In Focus
  6. Yaron WerberPositiveOct 30, 2026· Biotech Hangout

    Amgen enrolled its Lp(a) study in 16 months, faster than Novartis.

    “they are leap and bounce faster than anybody else recall they enrolled their lp little a study in 16 months”

    Listen at 20:39

    Open the episode · Episode 201 - October 30, 2026
  7. Sam FazeliPositiveOct 30, 2026· Biotech Hangout

    Amgen’s Delphi 305 data appeared practice-changing in small-cell lung cancer.

    “I did see at least that as a practice-changing data set.”

    Listen at 43:21

    Open the episode · Episode 201 - October 30, 2026
  8. Sam FazeliPositiveOct 30, 2026· Biotech Hangout

    Delphi 305 is likely to change small-cell lung-cancer standard of care.

    “this is standard of care changing.”

    Listen at 49:45

    Open the episode · Episode 201 - October 30, 2026
  9. Sam FazeliPositiveOct 30, 2026· Biotech Hangout

    Delphi 312 is expected to succeed after Delphi 305.

    “I'm pretty convinced will be successful too”

    Listen at 50:01

    Open the episode · Episode 201 - October 30, 2026
  10. Amgen is clearly under institutional accumulation.

    “a stock that's clearly... under accumulation here”

    Listen at 12:20

    Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In Focus
  11. Amgen presents an actionable buy setup.

    “a stock that's actionable here”

    Listen at 12:35

    Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In Focus
  12. Amgen is a solid blue-chip with a strong technical setup.

    “Amgen is just a really solid blue-chip name and great technical setup here”

    Listen at 12:51

    Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In Focus
  13. Amgen tends to trade orderly, with ATR around 2.5%.

    “the ATR is down around the 2.5%, so it tends to trade fairly orderly”

    Listen at 13:40

    Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In Focus
  14. Amgen is developing a treatment similar to Novartis's cardiovascular drug.

    “Amgen is working on a similar treatment.”

    Listen at 5:27

    Open the episode · Apple Event, Treasury Auction Fill Time Before PPI
  15. Nathan HagerNegativeSep 8, 2026· Stock Movers

    Novartis’s news is dragging down Amgen shares.

    “shares of Amgen, for instance, which is also in late-stage testing of its own heart disease drug, also being dragged down as a result of this news from Novartis.”

    Listen at 1:26

    Open the episode · Novartis Drop; Boston Scientific Cyberattack; Intel Rises
  16. John TuckerNegativeSep 8, 2026· Stock Movers

    Novartis’s news is dragging down Amgen shares.

    “Shares of Amgen, for instance, which is in late-stage testing of its own heart disease medication, also being dragged down by this news from Novartis.”

    Listen at 1:31

    Open the episode · Novartis and Boston Scientific Slide; Intel Price Hikes
  17. Amgen’s cardiovascular drug will likely produce a Novartis-like trial readout.

    “it's likely that Amgen's drug is probably going to give a similar readout”

    Listen at 6:05

    Open the episode · AI Stocks Lead, Blue Chips Lag In Down Session: AMD, Magnite, TVTX In Focus
  18. Amgen could drop its cardiovascular drug without much further stock decline.

    “Amgen could remove that drug from its portfolio, and the stock probably wouldn't go down all that much more.”

    Listen at 7:00

    Open the episode · 'Mad Money w/ Jim Cramer 9/8/26
  19. Jim CramerPositiveJan 31, 2026· Mad Money w/ Jim Cramer

    Amgen stock could rise on earnings and weight-loss-drug news

    “That plus good earnings and maybe some good news about this weight loss drug could send this Dow stock higher.”

    Listen at 4:39

    Open the episode · Mad Money w/ Jim Cramer 1/30/26
  20. Jim CramerPositiveJan 31, 2026· Mad Money w/ Jim Cramer

    Amgen’s pipeline, earnings, and weight-loss news could lift its stock.

    “could send this Dow stock higher”

    Listen at 4:42

    Open the episode · Mad Money w/ Jim Cramer 1/30/26
  21. Jim CramerPositiveNov 21, 2025· Mad Money w/ Jim Cramer

    Amgen is another stock Cramer favors alongside Regeneron.

    “I'll give you two for so is Amgen.”

    Listen at 31:19

    Open the episode · Mad Money w/ Jim Cramer 11/20/25
  22. Jim CramerNegativeNov 6, 2025· Mad Money w/ Jim Cramer

    Amgen needs to broaden its portfolio through strategic action.

    “I think Amgen needs to do something because they've got to broaden the portfolio”

    Listen at 9:21

    Open the episode · Mad Money w/ Jim Cramer 11/5/25

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.